Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084838 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00084838 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 25 participants.
The verdict
NCT00084838, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving intrathecal and systemic combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system (CNS) atypical teratoid/rhabdoid tumors.
Interventions
- DRUG cisplatin
- DRUG cyclophosphamide
- BIOLOGICAL filgrastim
- DRUG dexrazoxane hydrochloride
- DRUG cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2003-02 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00084838
The ClinicalTrials.gov registry entry for NCT00084838 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00084838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00084838 about?
NCT00084838 is a clinical study titled "Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT". RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: This phase I...
What is the current status of trial NCT00084838?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2003-02. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00084838?
The interventions under investigation include: cisplatin (DRUG), cyclophosphamide (DRUG), filgrastim (BIOLOGICAL), dexrazoxane hydrochloride (DRUG), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00084838?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.